SBIR Commercialization Plan 2026: Complete Writing Guide

SBIR Phase II Commercialization Plan Requirements by Agency

The Structure of a Phase II Commercialization Plan

Most agency solicitations organize the commercialization plan around the same core elements, even when they use different section names. A well-structured Phase II commercialization plan addresses these areas:

1. Market Opportunity. Who are the customers, what is the market size, and how does the problem you solve create commercial value?

2. Technical Differentiation. How does your technology compare to what customers currently use? What is your sustainable competitive advantage?

3. Customer Validation. What evidence do you have that customers want this product?

4. Business Model. How will you make money? What is your pricing strategy, revenue model, and path to profitability?

5. Go-to-Market Strategy. How will you reach your first 10 customers? Your first 100? What are the sales channels and partnership strategies?

6. Team and Commercialization Capacity. Who on your team has business development, sales, or market access experience?

7. Phase III Funding Plan. What capital sources will fund commercialization after the SBIR ends?

Section 1: Market Opportunity

The market opportunity section is where the majority of commercialization plans are weakest. The single most common problem: vague market size claims.

Claims like "the global diagnostic imaging market exceeds $40 billion" or "the US healthcare IT market is projected to reach $390 billion by 2030" communicate nothing useful to reviewers. These are not your market. They are the industry your market is in.

Reviewers want to know: what is the addressable market for the specific product you are developing? Who specifically will buy it? At what price point?

A credible market analysis looks like this: "Our product targets hospital pathology departments performing immunohistochemistry (IHC) staining in the United States. There are approximately 5,800 hospital-based pathology laboratories in the US (CAP, 2024). Our target customer is the laboratory that performs over 500 IHC tests per month. Based on our customer interviews, approximately 1,200 of these laboratories fit that profile. At a target price of $28,000 per unit with annual service contracts of $4,000, our serviceable addressable market is approximately $48M in equipment and $4.8M annually in service revenue."

That is a real market analysis. It has numbers, sources, and specificity. It tells reviewers you understand your customer.

What the market analysis should include:

• Total addressable market (TAM) with source, and more importantly, serviceable addressable market (SAM)
• Number of potential customers (not the market size in dollars for the whole industry)
• Customer segmentation: who is your beachhead customer?
• Market trends supporting timing: why now?
• Regulatory environment if relevant (FDA pathway, reimbursement codes, procurement rules)

Section 2: Technical Differentiation

Competitive advantage analysis is where technical investigators often confuse technical superiority with commercial advantage.

"Our system achieves 3x higher sensitivity than competing instruments" is a technical claim. Whether it is a commercial advantage depends on: does the customer value sensitivity above all other purchase criteria? Or do they primarily care about cost, throughput, ease of use, service support, or integration with existing systems?

The technical differentiation section should:

1. Identify 3-5 competing solutions, including the incumbent solution customers currently use
2. Compare your technology to each on dimensions that customers actually use to make purchase decisions (not dimensions where you happen to win)
3. State your sustainable competitive advantage clearly: what can't competitors replicate quickly?

A competitive advantage is sustainable if it comes from patents, proprietary data, regulatory approval, deep customer relationships, or manufacturing know-how that takes years to develop. "We are 6 months ahead of the competition" is not sustainable. "We have three issued patents covering the core mechanism, and our team has 20 years of relationships with the 50 largest hospital procurement managers" is.

Section 3: Customer Validation

Customer validation is the section that most directly distinguishes Phase II applications from research proposals. Reviewers want evidence that real customers have engaged with your technology and expressed intent to buy.

The strongest forms of customer validation, in descending order of impact:

1. Paying customers or signed contracts. If you have sold anything, even a pilot, that is powerful evidence.
2. Letters of intent (LOIs). A letter from a named company saying they intend to be a customer if the product reaches specified milestones. Not generic "interest letters." LOIs with specific terms and conditions.
3. Memoranda of understanding (MOUs). Partnership agreements with distributors, manufacturers, or large customers.
4. Named pilot customers in progress. Ongoing unpaid pilots with identified companies are strong evidence.
5. Customer interviews with named contacts. "We have conducted 45 customer discovery interviews with directors of operations at 38 distinct companies including X, Y, and Z, and 89% stated they would purchase at our target price point if the specifications are met."

What does NOT constitute strong customer validation: generic survey results without methodology, unsolicited interest emails from strangers, or letters from academic colleagues expressing scientific interest.

If you are proposing a new product for government procurement, the validation looks different: you need evidence of specific procurement programs, named contracting officers you have spoken with, and realistic program budget windows.

Section 4: Business Model

The business model section answers: how will this company generate revenue, and when will it be profitable?

A complete business model description includes:

• Revenue model. Product sales, subscription, licensing, service contract, or some combination. Be specific.
• Pricing. What will you charge? Why? What is the customer's cost of the problem you solve, and how does your price compare to that cost?
• Unit economics. What does it cost you to produce one unit, and what do you sell it for? What is the gross margin?
• Path to profitability. With the Phase II award and anticipated Phase III funding, what is the timeline to break-even?
• Capital requirements. How much capital do you need beyond the Phase II award to reach commercialization, and where will it come from?

The most common business model mistake: presenting financial projections without assumptions. "We project $10M revenue in Year 3" means nothing to reviewers without the underlying model: how many customers, at what price, with what sales cycle.

What Makes a Commercialization Plan Score Outstanding

The characteristics of plans that score Outstanding vs. Good are consistent:

Outstanding plans know their customer. The investigator has spent time with real customers, understands the purchasing process, knows who makes the decision, and has validated that the customer will pay the proposed price. This knowledge shows throughout the plan.

Outstanding plans have a team with commercial experience. A chief commercial officer, a business development advisor, or a co-founder with prior startup exits signals to reviewers that the company has thought about the business, not just the science. If you don't have this on your team, a named commercial advisor with relevant experience is the next best thing.

Outstanding plans acknowledge competition honestly. Reviewers who know the field will know your competitors. A plan that says "there are no direct competitors" is an immediate credibility problem. A plan that names competitors, explains their weaknesses, and explains why your approach is better demonstrates market knowledge.

Outstanding plans have customer validation at a level appropriate to the technology readiness. For a technology at TRL 4-5, early customer interviews and LOIs are appropriate. For a technology at TRL 7-8, you should have pilot customers or early sales. The validation evidence must match where the technology actually is.

What the SBIR Commercialization Requirements Don't Tell You

The commercialization plan is read by non-technical reviewers. SBIR Phase II panels often include a commercialization reviewer with business background, not just technical expertise. Write the commercialization plan so that someone with no technical background in your field can understand the business opportunity and competitive dynamics.

Phase I commercialization foundation matters enormously. Agencies track commercialization outcomes of their SBIR portfolios. Program managers know which companies succeed in Phase III. If your company has prior SBIR Phase II awards and commercialization track record, that context appears in your application and influences reviewers. If this is your first Phase II, the absence of track record is neutral, but demonstrating that you've spent Phase I laying commercial groundwork (customer interviews, early sales, partnership discussions) partially compensates.

Budget allocation for commercialization activities. In Phase II, you can budget for commercialization activities, including market research, IP protection, customer development, and business development travel. A Phase II budget that includes zero commercialization spend suggests you don't plan to pursue commercial outcomes.

NSF SBIR and NIH SBIR weight commercialization differently. NSF SBIR, managed by the NSF TIP directorate, weights commercial potential approximately equally with technical merit. NIH SBIR weights commercialization somewhat lower than technical merit for therapeutics and diagnostics but weights it heavily for platform technologies and tools. Know your agency's specific weighting.

Related SBIR Guides

• SBIR Grants: The Complete Guide
• SBIR Phase 1 Grant Guide
• SBIR Phase 2 Guide
• SBIR vs STTR: Which Is Right for Your Company
• NIH SBIR/STTR Guide
• How to Write an SBIR Proposal That Scores Well

How Grantsights Checked This Guide

Source review by Grantsights: we checked SBA SBIR/STTR policy guidance, NIFA commercialization plan guidance (opens in a new tab), agency Phase II instructions, SBIR.gov, Grants.gov, USASpending.gov before this update. The practical gap is that official guidance tells you to discuss commercialization, but it rarely shows how reviewers separate a real business case from a technical continuation plan.

According to NIFA, successful SBIR/STTR work aims to bring products, processes, technologies, or services to market or government use. According to SBIR.gov, SBIR Phase II generally supports further research and development based on Phase I results. According to SBA policy, commercialization includes developing, producing, and delivering products or services for commercial markets or federal use. According to agency Phase II instructions, plan length is set by each agency (12 pages at NIH, up to 15 at NSF). According to USASpending.gov, prior award history can show whether an agency has funded similar Phase II technologies and companies.

According to NIFA, Phase I applicants should begin considering the commercialization strategy before Phase II. According to SBIR.gov, Phase II is normally based on Phase I results and further R&D need. According to SBA policy reviewed by Grantsights, commercialization can mean sale or use by commercial markets or the federal government. According to USASpending.gov, Phase II award records can help identify agency topic clusters and repeat award patterns.

Decision checklist: identify the buyer, price, sales channel, validation proof, Phase III capital source, regulatory or procurement path, and commercial lead before writing the plan. For deeper mechanics, pair this with the SBIR grants complete guide, NIH grants guide, NSF grants guide, and live SBIR opportunities.

What Official Sources Don't Tell You

Official templates do not tell you when the business case is too thin. An SBIR commercialization plan is a bad fit if it claims a huge market without a reachable buyer, lists generic partners instead of named validation, or has no Phase III capital path. For example, one diagnostics company with strong assay data but no reimbursement, FDA, or hospital purchasing plan will likely lose commercialization points even if the science is strong. Use the free Grantsights grant search to compare active SBIR opportunities.

The SBIR program exists to fund R&D that has commercial potential. Phase I tests feasibility. Phase II funds full development toward a product or service that customers will use. The commercialization plan is where you make the case that the development will succeed in a market.

Most investigators write commercialization plans the way they write research proposals: describing what the technology does, why it's novel, and what problems it could solve. That is the wrong frame. A commercialization plan is a business document. Reviewers are asking: is there a real business here? Can this team build it?

Commercialization plans tend to fall into three groups. Some make reviewers believe in the business. Many are technically compliant but don't distinguish themselves. Others raise commercial viability concerns that affect the overall score.

This guide covers what each section of the commercialization plan should accomplish, what reviewers score, and the specific problems that cause otherwise strong applications to fail on commercialization.

Sources

• SBA SBIR Policy Directive (2019, updated 2023): www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf (opens in a new tab)
• NIH SBIR/STTR Application Guide: grants.nih.gov/grants/funding/sbir.htm (opens in a new tab)
• NSF SBIR/STTR Program Information: new.nsf.gov/funding/initiatives/sbir-sttr (opens in a new tab)
• SBIR.gov Company Registry and Award Database: www.sbir.gov (opens in a new tab)
• America's Seed Fund (NSF SBIR): seedfund.nsf.gov (opens in a new tab)